LMAT:NASDAQLeMaitre Vascular, Inc. Analysis

LeMaitre Vascular is trading at $117.39, just below its technical resistance of $118.01 and well above the $104 support level, while the 20‑day SMA (110.47) sits above both the 50‑day (102.58) and 200‑day (91.07) averages, confirming a bullish price structure. Momentum indicators are mixed: the RSI of 71.6 signals an overbought condition, yet the MACD remains bullish with the line (3.14) above its signal (2.86) and a positive histogram. Volume is on a decreasing trend, suggesting waning buying pressure as the stock nears its ceiling. The equity carries a low beta of 0.57, indicating modest market sensitivity, but 30‑day volatility is elevated at 24%, and the max drawdown of –20% highlights downside risk in a correction. Valuation metrics are stretched; the trailing P/E of 46.6 far exceeds the industry average of 26.2, and the DCF‑derived fair value of $61.45 implies the market price is more than double intrinsic estimates, yielding a downside potential of roughly 5%. Despite the premium, fundamentals are solid: revenue grew 15.7% year‑over‑year to $249.6 M, gross margin stands at 70%, operating margin at 21.8%, and free cash flow is $47.3 M. The balance sheet is healthy with $359 M cash versus $186 M debt (debt‑to‑equity 47%), and the dividend yield of 0.85% is supported by a modest payout ratio of 32%. The company benefits from a diversified geographic footprint and a stable dividend, but the current “Extreme Greed” market sentiment (fear‑greed index 88.6) and overvaluation caution against immediate upside.
Overall, the stock appears poised for a short‑term pullback near resistance, while its strong earnings profile and defensive cash position support a longer‑term view that hinges on a price correction toward intrinsic value.